103 related articles for article (PubMed ID: 7408404)
1. Massive propranolol metabolite retention during maintenance hemodialysis.
Stone WJ; Walle T
Clin Pharmacol Ther; 1980 Oct; 28(4):449-55. PubMed ID: 7408404
[TBL] [Abstract][Full Text] [Related]
2. Effect of dose and uremia on plasma and urine profiles of propranolol metabolites.
Schneck DW; Pritchard JF; Gibson TP; Vary JE; Hayes AH
Clin Pharmacol Ther; 1980 Jun; 27(6):744-55. PubMed ID: 7379441
[TBL] [Abstract][Full Text] [Related]
3. Kinetic and clinical observations in cyanotic children on propranolol therapy.
Riopel DA; Walle T
Clin Pharmacol Ther; 1980 Dec; 28(6):743-50. PubMed ID: 7438690
[TBL] [Abstract][Full Text] [Related]
4. Metabolism of propranolol in the human maternal-placental-foetal unit.
Smith MT; Livingstone I; Eadie MJ; Hooper WD; Triggs EJ
Eur J Clin Pharmacol; 1983; 24(6):727-32. PubMed ID: 6884410
[TBL] [Abstract][Full Text] [Related]
5. Propranolol, propranolol glucuronide, and naphthoxylactic acid in breast milk and plasma.
Smith MT; Livingstone I; Hooper WD; Eadie MJ; Triggs EJ
Ther Drug Monit; 1983; 5(1):87-93. PubMed ID: 6845404
[TBL] [Abstract][Full Text] [Related]
6. 4-Hydroxypropranolol and its glucuronide after single and long-term doses of propranolol.
Walle T; Conradi EC; Walle UK; Fagan TC; Gaffney TE
Clin Pharmacol Ther; 1980 Jan; 27(1):22-31. PubMed ID: 7351114
[TBL] [Abstract][Full Text] [Related]
7. Plasma concentrations of propranolol and 4-hydroxy-propranolol at steady-state in neurological patients: intersubject and intrasubject correlations with dose.
Albani F; Riva R; Baldrati A; Cortelli P; Perucca E; Procaccianti G; Baruzzi A
Int J Clin Pharmacol Res; 1984; 4(1):19-23. PubMed ID: 6469429
[TBL] [Abstract][Full Text] [Related]
8. Fluorometric TLC determination of free and conjugated propranolol, naphthoxylactic acid, and p-hydroxypropranolol in human plasma and urine.
Garceau Y; Davis I; Hasegawa J
J Pharm Sci; 1978 Jun; 67(6):826-31. PubMed ID: 660467
[TBL] [Abstract][Full Text] [Related]
9. Plasma concentrations of propranolol and 4-hydroxypropranolol during chronic oral propranolol therapy.
Wong L; Nation RL; Chiou WL; Mehta PK
Br J Clin Pharmacol; 1979 Aug; 8(2):163-7. PubMed ID: 486291
[TBL] [Abstract][Full Text] [Related]
10. Measurement of naphthoxylactic and naphtoxyacetic acid in human plasma following propranolol administration.
Pritchard F; Schneck D; Hayes A
Res Commun Chem Pathol Pharmacol; 1979 Feb; 23(2):279-86. PubMed ID: 461953
[TBL] [Abstract][Full Text] [Related]
11. Nonlinear formation of propranolol metabolites in dogs after portacaval transpositions.
Lo MW; Pond SM; Effeney DJ; Silber BM; Riegelman S; Tozer TN
J Pharmacokinet Biopharm; 1984 Aug; 12(4):401-12. PubMed ID: 6527232
[TBL] [Abstract][Full Text] [Related]
12. Chronic propranolol administration during pregnancy. Maternal pharmacokinetics.
Smith MT; Livingstone I; Eadie MJ; Hooper WD; Triggs EJ
Eur J Clin Pharmacol; 1983; 25(4):481-90. PubMed ID: 6653642
[TBL] [Abstract][Full Text] [Related]
13. Propranolol in hypertensive dialysis patients: efficacy and compliance.
Briggs WA; Lowenthal DT; Cirksena WJ; Price WE; Gibson TP; Flamenbaum W
Clin Pharmacol Ther; 1975 Nov; 18(5 Pt 1):606-12. PubMed ID: 1183140
[TBL] [Abstract][Full Text] [Related]
14. Urine and plasma propranolol.
Andreasen F; Jakobsen P; Kornerup HJ; Pedersen EB; Pedersen OL
Clin Pharmacol Ther; 1983 Jan; 33(1):10-8. PubMed ID: 6848294
[TBL] [Abstract][Full Text] [Related]
15. Didanosine pharmacokinetics in patients with normal and impaired renal function: influence of hemodialysis.
Singlas E; Taburet AM; Borsa Lebas F; Parent de Curzon O; Sobel A; Chauveau P; Viron B; al Khayat R; Poignet JL; Mignon F
Antimicrob Agents Chemother; 1992 Jul; 36(7):1519-24. PubMed ID: 1510449
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and effects of propranolol in terminal uraemic patients and in patients undergoing regular dialysis treatment.
Bianchetti G; Graziani G; Brancaccio D; Morganti A; Leonetti G; Manfrin M; Sega R; Gomeni R; Ponticelli C; Morselli PL
Clin Pharmacokinet; 1976; 1(5):373-84. PubMed ID: 1017154
[TBL] [Abstract][Full Text] [Related]
17. Quantitative account of propranolol metabolism in urine of normal man.
Walle T; Walle UK; Olanoff LS
Drug Metab Dispos; 1985; 13(2):204-9. PubMed ID: 2859169
[TBL] [Abstract][Full Text] [Related]
18. Stereospecific assay for (-)- and (+)-propranolol in human and dog plasma.
Silber B; Riegelman S
J Pharmacol Exp Ther; 1980 Dec; 215(3):643-8. PubMed ID: 7441523
[TBL] [Abstract][Full Text] [Related]
19. The effect of isohydric hemodialysis on the binding and removal of uremic retention solutes.
Etinger A; Kumar SR; Ackley W; Soiefer L; Chun J; Singh P; Grossman E; Matalon A; Holzman RS; Meijers B; Lowenstein J
PLoS One; 2018; 13(2):e0192770. PubMed ID: 29470534
[TBL] [Abstract][Full Text] [Related]
20. Effects of diltiazem on the disposition and metabolism of the enantiomers of propranolol in the dog during multiple oral dosing.
Lankford SM; Maskasame C; Bai SA
Drug Metab Dispos; 1994; 22(5):776-87. PubMed ID: 7835231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
